Is Broach Lifecare overvalued or undervalued?

As of 28 August 2025, the valuation grade for Broach Lifecare has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE Ratio of 15.42, an EV to EBITDA of 15.35, and a ROCE of 13.19%.
In comparison to its peers, Broach Lifecare's valuation stands out favorably against Max Healthcare, which has a PE Ratio of 93.61, and Apollo Hospitals, with a PE Ratio of 70.56. This suggests that Broach Lifecare offers a more attractive investment opportunity relative to these higher-valued competitors. Additionally, while the stock has underperformed over the past year with a return of -43.44%, it has shown resilience with a year-to-date return of 17.59%, contrasting with the Sensex's 2.48% return.